Summary of Study ST003201
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001995. The data can be accessed directly via it's Project DOI: 10.21228/M8VB2V This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST003201 |
| Study Title | Molecular signatures of xenograft colon cancer models treated with topotecan: A Mass Spectrometry-Based Study |
| Study Summary | Colorectal cancer (CRC) is one of the most common cancers worldwide. Despite improvement in standardized screening methods and the development of promising therapies, the 5-year survival rates are as low as 10% in the metastatic setting. Metabolomics, the study of metabolites on a large scale, has provided new insight into disease diagnosis and biomarkers identification. We chose topotecan as an anti-cancer drug in this context because, as far as we know, there are no studies examining the effect of this anti-cancer drug on metabolic alterations in CRC. In this study, untargeted metabolomic analysis study was performed to compare between four animal groups; HCT-116 xenograft models treated with topotecan, untreated HCT-116 xenograft models (vehicle controls), positive controls, and negative controls, using UHPLC-ESIQTOF-MS platform. One way ANOVA analysis discovered 53 statistically significant metabolites among all four groups (p <0.05). T-test revealed that 15 metabolites were statistically significant among vehicle controls and negative controls. Also, 20 metabolites were statistically significant among the potential respondersto topotecan and the vehicle controls. In addition, only 1 metabolite was statistically significant among the positive and negative control. Ultimately, by analyzing metabolomic profiles, our findings can create a map that can be utilized to assess the anticancer activity of topotecan in CRC. More studies with larger number of models are needed to verify the implication of the significantly altered metabolites and metabolic pathways in diagnosing and treating CRC. |
| Institute | Sharjah Institute for Medical Research |
| Last Name | Facility |
| First Name | Core |
| Address | M32, SIMR, College of Pharmacy, Health Sciences, University of Sharjah, Sharjah, UAE, Sharjah, 000, United Arab Emirates |
| tims-tof@sharjah.ac.ae | |
| Phone | +971 6 5057656 |
| Submit Date | 2024-05-13 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | d |
| Analysis Type Detail | LC-MS |
| Release Date | 2024-06-04 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Subject:
| Subject ID: | SU003320 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
| Gender: | Male |
